Prostate Health Index (PHI) Test

PSA (prostate-specific antigen) testing has been the primary prostate cancer screening tool for decades, but its major limitation is poor specificity: PSA is elevated not only in prostate cancer but in benign prostatic hyperplasia (BPH), prostatitis, and after physical activity involving the prostate. The result is that a large proportion of men with elevated PSA in the 4–10 ng/mL 'diagnostic grey zone' are referred for prostate biopsy when no cancer is…

The Prostate Health Index (PHI) solves this by combining three PSA-related measurements in a validated algorithm. Total PSA provides the overall antigen level. Free PSA is the fraction of PSA circulating unbound to serum proteins: a low free PSA percentage (free PSA/total PSA ratio) is associated with higher cancer probability, while benign conditions tend to produce proportionally more free PSA. The [-2]proPSA (p2PSA) is the most cancer-specific isoform…

The PHI formula combines these three values: PHI = (p2PSA / free PSA) × √total PSA. In clinical validation studies, including the European Randomised Study of Screening for Prostate Cancer (ERSPC), PHI has demonstrated superior sensitivity for clinically significant prostate cancer compared to total PSA or %fPSA alone, while substantially reducing the biopsy rate in men who are ultimately cancer-free.